1. Home
  2. BRBI vs TECX Comparison

BRBI vs TECX Comparison

Compare BRBI & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRBI

BRBI BR Partners S.A. ADSs

N/A

Current Price

$14.46

Market Cap

394.5M

Sector

Finance

ML Signal

N/A

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

N/A

Current Price

$33.99

Market Cap

393.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BRBI
TECX
Founded
2009
2019
Country
Brazil
United States
Employees
N/A
51
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
394.5M
393.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BRBI
TECX
Price
$14.46
$33.99
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$80.40
AVG Volume (30 Days)
1.6K
552.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
5.33%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$33.39
N/A
Revenue Next Year
$17.24
N/A
P/E Ratio
$11.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.54
$13.70
52 Week High
$67.01
$35.99

Technical Indicators

Market Signals
Indicator
BRBI
TECX
Relative Strength Index (RSI) 47.64 75.47
Support Level $13.82 $16.83
Resistance Level $14.34 N/A
Average True Range (ATR) 0.26 2.45
MACD -0.11 1.27
Stochastic Oscillator 22.58 87.37

Price Performance

Historical Comparison
BRBI
TECX

About BRBI BRBI BR Partners S.A. ADSs

BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: